ALDX

Aldeyra Therapeutics Inc

0.5603

Oct 30 • 3:59 PM ET -0.0988 (-14.99%)

0.5623

Aftermarket • 7:39 PM ET +0.0020 (0.36%)

Healthcare Biotechnology USA Nano NASD

Peers: OKYO BLCO KALA LENZ TARS OCUL IRD EYPT KPRX HROW

| Held by: VTI VXF VHT IWC PRFZ QQQS DFAS BTEC

Scroll to Statements

Index	-
Market Cap	33.80M
Enterprise Value	-11.15M
Income	-23.05M
Sales	0.00M
Book/sh	0.63
Cash/sh	0.75
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	May 02, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.89
P/C	0.75
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.84
Current Ratio	4.84
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.38
EPS next Y	-0.28
EPS next Q	-0.09
EPS this Y	39.29%
EPS next Y	18.24%
EPS next 5Y	36.26%
EPS past 3/5Y	19.04% 12.61%
Sales past 3/5Y	- -
EPS Y/Y TTM	54.84%
Sales Y/Y TTM	-
EPS Q/Q	44.44%
Sales Q/Q	-
Earnings	Jul 31
EPS/Sales Surpr.	-16.13% -

Insider Own	3.70%
Insider Trans	12.61%
Inst Own	60.49%
Inst Trans	-4.33%
ROA	-34.80%
ROE	-49.48%
ROIC	-60.85%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-26.50%
SMA50	-51.12%
SMA200	-75.41%
Trades

Shs Outstand	60.32M
Shs Float	58.10M
Short Float	5.48%
Short Ratio	2.79
Short Interest	3.19M
52W High	5.93 -90.55%
52W Low	0.60 -7.16%
Volatility	11.60% 12.14%
ATR (14)	0.09
RSI (14)	24.82
Beta	1.23
Rel Volume	0.78
Avg Volume	1.14M
Volume	896,646

Perf Week	-13.76%
Perf Month	-56.57%
Perf Quarter	-63.38%
Perf Half Y	-64.76%
Perf YTD	-89.18%
Perf Year	-88.86%
Perf 3Y	-63.62%
Perf 5Y	-93.84%
Perf 10Y	-89.33%
Recom	1.40
Target Price	6.60
Prev Close	0.66
Price	0.56
Change %	-14.99%

Consensus

Strong Buy

Avg. Price Target

$6.60

Implied Upside

+1,077.9%

Analysts13incl. previous ratings

Rating Distribution12 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 18, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral	$2	+257.0%
Apr 03, 2024	Upgrade	OOppenheimer	Perform → Outperform	$10	+1,684.8%
Apr 02, 2024	Resumed	HH.C. Wainwright	Buy	$10	+1,684.8%
Apr 27, 2022	Resumed	HH.C. Wainwright	Buy	$15	+2,577.1%
Feb 08, 2021	Initiated	HH.C. Wainwright	Buy	$26	+4,540.4%
Dec 16, 2020	Initiated	BBerenberg	Buy	$32	+5,611.2%
Oct 30, 2020	Initiated	JJefferies	Buy	$24	+4,183.4%
Oct 16, 2020	Initiated	BBTIG Research	Buy	$29	+5,075.8%
Sep 22, 2020	Initiated	AAlliance Global Partners	Buy	$32	+5,611.2%
May 12, 2020	Initiated	OOppenheimer	Outperform	$12	+2,041.7%
Dec 04, 2018	Initiated	CCitigroup	Buy	$23	+4,004.9%
Sep 26, 2018	Reiterated	CCantor Fitzgerald	Overweight	$23 → $30	+5,254.3%
Sep 13, 2018	Initiated	JJanney	Buy
Jan 26, 2018	Initiated	SSeaport Global Securities	Buy	$13	+2,220.2%
Sep 26, 2016	Initiated	HH.C. Wainwright	Buy	$18	+3,112.6%
Jul 01, 2016	Initiated	SStifel	Buy	$16	+2,755.6%
Jul 01, 2015	Initiated	CCanaccord Genuity	Buy	$16	+2,755.6%
Mar 25, 2015	Initiated	CChardan Capital Markets	Buy	$16	+2,755.6%
Mar 20, 2015	Reiterated	HH.C. Wainwright	Buy	$13 → $14	+2,398.7%
Nov 18, 2014	Initiated	HH.C. Wainwright	Buy	$13	+2,220.2%

Sep-29-26 10:49AM	Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter (InvestorsHub) +13.79%
07:00AM	Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease (Business Wire)
Sep-28-26 04:30PM	Aldeyra Therapeutics to Host Regulatory Update Webcast (Business Wire)
Jun-09-26 08:30PM	Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors (Business Wire)
Jun-02-26 07:01AM	Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (Business Wire)
09:02AM	Loading…
Apr-07-26 09:02AM	Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Apr-01-26 07:30AM	Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ALDX (Business Wire)
Mar-18-26 07:45AM	Aspens fresh Parkinsons data; Aldeyra tanks following FDA rejection (BioPharma Dive) +14.52%
06:18AM	FDA issues CRL to Aldeyras reproxalap drug application (Hospital Management)
Mar-17-26 04:33PM	Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile) -70.69%
08:30AM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire)
Feb-26-26 09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-25-26 03:29PM	Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference (MarketBeat) +5.37%
Feb-19-26 09:55AM	Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? (Zacks)
Feb-18-26 07:01AM	Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Business Wire)
09:55AM	Loading…
Feb-03-26 09:55AM	Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know (Zacks)
09:40AM	Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? (Zacks)
Dec-15-25 07:30PM	Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease (Business Wire) -12.11% +33.08%
Nov-13-25 07:00AM	Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast (Business Wire) -5.28%
Nov-11-25 07:01AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (Business Wire)
Nov-06-25 07:00AM	Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET (Business Wire)
Oct-29-25 08:16AM	Aldeyra reshuffles pipeline, culling asset despite Phase II success (Clinical Trials Arena)
Oct-28-25 07:01AM	Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules (Business Wire)
Sep-03-25 07:01AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-28-25 07:01AM	Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma (Business Wire)
Aug-23-25 04:20AM	JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 (Insider Monkey)
Aug-19-25 07:01AM	Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Treatment of Retinitis Pigmentosa (Business Wire)
Aug-06-25 07:01AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Business Wire)
Jul-24-25 07:00AM	Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa (Business Wire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
07:00AM	Loading…
07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-15-25 12:00PM	Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Amgen (AMGN) This Year? (Zacks)
Jun-26-25 07:00AM	Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +10.26%
Jun-17-25 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
May-29-25 07:01AM	Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference (Business Wire)
May-05-25 06:34PM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission (Business Wire) -22.22%
04:00PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap (Business Wire)
Apr-29-25 11:42AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-28-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-24-25 01:57PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire) +9.50%
Apr-21-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
10:52AM	Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity (Seeking Alpha)
08:49AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-18-25 02:52PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
11:23AM	ALDX INVESTOR NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified to Contact BFA Law About How to Potentially Recover Losses (Newsfile)
Apr-17-25 07:00AM	Aldeyra Therapeutics Appoints Chip Clark to Board of Directors (Business Wire) +8.96%
Apr-16-25 05:23PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire) -8.64%
Apr-15-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-11-25 01:26PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
07:43AM	ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. Violate the Securities Laws? Investors are Notified to Contact BFA Law (NASDAQ:ALDX) (GlobeNewswire)
Apr-10-25 09:30AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman (PR Newswire)
Apr-09-25 05:00PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-08-25 04:51AM	After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (Seeking Alpha)
03:08AM	ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law (Newsfile)
Apr-06-25 07:08AM	ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations (Newsfile)
Apr-03-25 10:24AM	Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter (Investopedia) -73.33%
08:00AM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire)
Mar-10-25 07:00AM	Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference (Business Wire)
Feb-05-25 03:24AM	Aldeyra Therapeutics, Inc. (ALDX) Notice: Grabar Law Office Is Investigating Claims for Long-Term Shareholders (Newsfile) +6.73%
Feb-04-25 07:00AM	Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-20-25 03:28PM	Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-09-24 10:05AM	Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? (Zacks)
Dec-02-24 07:00AM	Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-18-24 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement (Business Wire) +11.64%
Nov-14-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-31-24 07:00AM	Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting (Business Wire)
Oct-03-24 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Sep-05-24 07:00AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-30-24 10:38AM	Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory (Insider Monkey) +7.07%
Aug-09-24 06:32AM	Aldeyras Phase III clinical trial of Reproxalap meets primary endpoint (Clinical Trials Arena) +21.72%
Aug-08-24 07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap (Business Wire) +28.53%
Aug-07-24 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap (Business Wire) -5.23%
Jun-20-24 07:00AM	Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable (Business Wire) -6.47%
Jun-14-24 06:32AM	Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial (Clinical Trials Arena)
Jun-13-24 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease (Business Wire)
Jun-12-24 07:00AM	Aldeyra Therapeutics to Host Investor Roundtable Q&A (Business Wire)
May-29-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? (Zacks) +12.70%
May-08-24 03:12PM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study (MT Newswires)
07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease (Business Wire)
May-03-24 08:52AM	ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
Apr-25-24 07:00AM	Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day (Business Wire)
Apr-22-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-18-24 07:00AM	Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 (Business Wire)
Apr-06-24 06:37AM	Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why (Zacks)
Apr-04-24 12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal) +12.89%
Apr-03-24 02:58PM	Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval (Barrons.com) +16.90%
Mar-28-24 07:00AM	Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease (Business Wire) +6.17%
Mar-27-24 01:21PM	Notice to Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors (Newsfile) +5.48%
Mar-13-24 02:33AM	Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares (GuruFocus.com)
Mar-06-24 09:40AM	Here's Why You Should Invest in Aldeyra (ALDX) Stock Now (Zacks)
Feb-06-24 07:00AM	Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +7.05%
Jan-04-24 07:00AM	Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases (Business Wire)
Dec-19-23 07:27AM	UPDATE 1-Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study (Reuters) +18.58%
07:05AM	Aldeyra Therapeutics' eczema drug succeeds in mid-stage study (Reuters)
07:00AM	Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX629 in Patients with Atopic Dermatitis (Business Wire)
Dec-18-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis (Business Wire)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brady Todd C	President and CEO	Jun 03 '26	Buy	1.67	250,000	418,450	1,721,298	Jun 05 04:19 PM
DOUGLAS RICHARD	Director	Mar 19 '26	Buy	1.40	70,000	98,000	195,000	Mar 20 04:17 PM
Alfieri Michael	Principal Financial Officer	Mar 18 '26	Buy	1.42	5,000	7,100	7,500	Mar 19 05:29 PM

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. It focuses on the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Ph.D.Dr. Todd C. Brady M.D.

Head of Finance and Principal Financial & Accounting OfficerMr. Michael Alfieri

Head of Investor RelationsDavid Burke

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALDX

Aldeyra Therapeutics Inc

Upgrade your Finviz experience